RecruitingNCT05804331
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
Sponsor
Western Sydney Local Health District
Enrollment
500 participants
Start Date
Mar 14, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- UGI neoplastic lesions \> 10mm
- Lesions for ESD limited to the mucosal and/or submucosal layer OR
- Lesions for EFTR limited to the muscularis propria layer OR
- Lesions for STER limited to the submucosal and/or muscularis propria layer
- Aged 18 years or older
Exclusion Criteria4
- Age less than 18
- Unable to give informed consent
- Pregnant or lactating patients
- Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05804331
Related Trials
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT072774391 location
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT074546422 locations
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT0692192817 locations
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
NCT055003913 locations